文献速递角膜与眼表疾病

KeraVio紫光发射眼镜联合核黄素滴眼治疗角膜扩张的临床结果:一项初步研究

Clinical outcomes of KeraVio using violet light: emitting glasses and riboflavin drops for corneal ectasia: a pilot study.
PubMed 文献 · Br J Ophthalmol · 2020-09-05

本研究评估了新型KeraVio技术(375nm紫光发射眼镜联合核黄素滴眼)治疗进展性角膜扩张的临床效果。20只严重进展眼疗效评估显示,治疗6个月期间Kmax平均变化为-0.81±3.34 D,显著优于治疗前1年的6.03±3.41 D(p=0.002)。结论认为每日治疗可阻止疾病进展且无安全性担忧。

要点

  • KeraVio治疗6个月使Kmax平均下降0.81 D,而治疗前1年平均增加6.03 D。
  • 20只严重进展眼中,4眼(20%)Kmax下降超过2 D,13眼(65%)变化在2 D以内,3眼(15%)增加2 D以上。
  • 80%患眼出现角膜基质分界线,1个月时深度为206.3±54.9 μm,未见内皮细胞密度显著下降等安全问题。

核心结论

  • 基于6个月结果,每日KeraVio治疗可阻止进展性角膜扩张的疾病进展,且无安全性担忧。

研究设计与样本

  • 前瞻性初步研究,纳入40只眼进行安全性评估,其中20只严重进展眼用于疗效评估。
  • 患眼每日佩戴375 nm、辐照度310 μW/cm2的紫光发射眼镜3小时,持续6个月,每次3小时照射期间在角膜上皮表面滴用核黄素溶液6次。
  • 主要终点为6个月内最大角膜曲率(Kmax)变化与基线前1年变化的比较。

主要发现

  • 基线前1年Kmax平均变化为6.03±3.41 D,6个月观察期内平均变化为-0.81±3.34 D(p=0.002)。
  • 6个月时,4眼(20%)Kmax下降超过2 D,13眼(65%)变化在2 D以内,3眼(15%)增加2 D以上。
  • 16眼(80%)可识别角膜基质分界线,1个月时深度为206.3±54.9 μm。
  • 未观察到内皮细胞密度显著下降、晶状体混浊或暂时性角膜混浊。

关键数值与推荐

  • 紫光波长375 nm,辐照度310 μW/cm2,每日佩戴3小时,持续6个月。
  • 核黄素溶液在每次3小时紫光照射期间滴于角膜上皮6次。
  • Kmax下降超过2 D定义为改善,变化在2 D以内定义为稳定,增加2 D以上定义为进展。

临床怎么用

  • 对于进展性角膜扩张患者,可考虑每日使用KeraVio(紫光发射眼镜联合核黄素滴眼)作为阻止疾病进展的无创治疗选择。
  • 治疗6个月后需评估Kmax变化及角膜基质分界线深度以判断疗效。

局限性

  • 本研究为初步研究,样本量较小(疗效评估20眼),随访时间仅6个月。
  • 未设对照组,长期疗效和安全性有待进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: We developed a novel technology consisting of violet light (VL)-emitting glasses and defined the combination of VL irradiation and riboflavin treatment as KeraVio. Our goal was to evaluate the clinical results of KeraVio in patients with progressive corneal ectasia. METHODS: Eyes were exposed to VL (375 nm, irradiance 310 μW/cm2)-emitting glasses for 3 hours daily for 6 months, and a riboflavin solution was administered onto the corneal epithelium six times during each 3-hour VL irradiation. The primary end point was a change in the maximum keratometry (Kmax) value over 6 months compared with that over the 1 year before baseline. RESULTS: The efficacy of KeraVio was evaluated in 20 eyes with severe progression, and its safety was evaluated in all 40 eyes. The mean changes in Kmax over the 1 year before baseline and during the 6-month observation period were 6.03±3.41 dioptres (D) and -0.81±3.34 D, respectively (p=0.002). At 6 months, the Kmax value decreased by more than 2 D in 4 eyes (20%), remained within 2 D in 13 eyes (65%), and increased by 2 D or more in 3 eyes (15%). The corneal stromal demarcation line was identified in 16 eyes (80%), and its depth was 206.3±54.9 μm at 1 month. No significant decrease in endothelial cell density, lenticular opacity or transient corneal haze was noted. CONCLUSION: Based on our 6-month results, daily treatment of progressive corneal ectasia with KeraVio can halt disease progression without any safety concerns. CLINICAL TRIAL REGISTRATION NUMBER: jRCTs032180217.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Kobashi H, Torii H, Toda I, et al. Clinical outcomes of KeraVio using violet light: emitting glasses and riboflavin drops for corneal ectasia: a pilot study. Br J Ophthalmol. 2020. PMID: 32892163. doi:10.1136/bjophthalmol-2020-316974

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。